Want to see SG:8YY full AI Analyst Report?
8YY Stock Chart & Stats
S$0.04
<S$0.01(3.70%)
At close: 4:00 PM EST
S$0.04
<S$0.01(3.70%)
Day’s Range― - ―
52-Week RangeS$0.02 - S$0.09
Previous CloseN/A
Volume13.75M
Average Volume (3M)412.95K
Market Cap
S$62.40M
Enterprise ValueS$79.86M
Total Cash (Recent Filing)S$557.00K
Total Debt (Recent Filing)S$2.41M
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,733,441,800
10 Day Avg. Volume410,990
30 Day Avg. Volume412,950
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)58.30
Price to Sales (P/S)16.93
P/FCF Ratio-247.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueBiolidics’ business model includes recurring consumables and repeat-test revenue tied to installed devices. This creates an annuity-like revenue stream that supports predictability and margin recovery over months, improving long-term commercial stability as the installed base grows.
2025 Revenue Rebound Signals TractionA ~197% revenue rebound to ~5.3m in 2025 indicates renewed commercial traction and improved market acceptance of products. Sustained top-line growth from a higher base helps absorption of fixed costs and is a necessary condition for achieving durable operating leverage once maintained.
Growing Asset BaseTotal assets rising to ~5.1m suggests the company invested in capabilities or inventory to support commercialization. An expanding asset base can enable higher throughput, support recurring sales, and provide tangible capacity to scale operations over the next several months.
Bears Say
Sustained Net Losses And Negative Cash FlowThe company remains loss-making with a ~4.0m net loss in 2025 and negative operating and free cash flow. Continued cash burn undermines self-funding, raises refinancing risk, and limits ability to invest in R&D, sales expansion, or margin improvement without external capital.
Meaningful Leverage Versus Thin EquityDebt of ~2.4m against modest equity (~1.5m) leaves limited balance-sheet cushion. Historical negative equity periods magnify refinancing and solvency risk: adverse results or slower cash recovery could force dilutive funding, constrain strategic options, and reduce resilience to shocks.
Margins And Operating Leverage UnprovenVolatile margins and repeated operating losses indicate the business has not demonstrated reliable operating leverage. Without consistent margin expansion, revenue growth may not translate to profitability, keeping the company dependent on external funding and limiting long-term viability.
Biolidics Ltd. News
8YY FAQ
What was Biolidics Ltd.’s price range in the past 12 months?
Biolidics Ltd. lowest share price was S$0.02 and its highest was S$0.09 in the past 12 months.
What is Biolidics Ltd.’s market cap?
Biolidics Ltd.’s market cap is S$62.40M.
When is Biolidics Ltd.’s upcoming earnings report date?
Biolidics Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 5 days.
How were Biolidics Ltd.’s earnings last quarter?
Currently, no data Available
Is Biolidics Ltd. overvalued?
According to Wall Street analysts Biolidics Ltd.’s price is currently Overvalued.
Does Biolidics Ltd. pay dividends?
Biolidics Ltd. does not currently pay dividends.
What is Biolidics Ltd.’s EPS estimate?
Biolidics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biolidics Ltd. have?
Biolidics Ltd. has 1,733,441,800 shares outstanding.
What happened to Biolidics Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Biolidics Ltd.?
Currently, no hedge funds are holding shares in SG:8YY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biolidics Ltd.
Embracing Future Holdings Limited, a Singapore-based medical technology firm, specializes in precision medicine, focusing on developing diagnostic solutions. Operating across Japan, Hong Kong, Thailand, Malaysia, and the United States, its business is structured into Cancer, Infectious Diseases, and Laboratory Services segments. The company's key innovations include the ClearCell FX1 System, an automated device that, using Streck Cell-free DNA BCT and EDTA tubes, isolates intact and viable circulating tumor cells (CTCs) from small blood samples. It also provides the CTChip FR1 biochip for separating CTCs from leukocytes, alongside offering general laboratory services. Established in 2009, the company was formerly known as Biolidics Limited, adopting its current name in June 2025.
Technical Analysis
Cordlife Group
―
ISEC Healthcare Ltd
―
Medtecs International Corporation Ltd.
―
AJJ Medtech Holdings Limited
―
Singapore Institute of Advanced Medicine Holdings Ltd.
―